ArticleOncotarget2018

CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition.

Priya K Gopalan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.